Company intelligence / Profile preview

Tevogen Bio

Warren, New Jersey, USAtevogen.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Completed proof-of-concept clinical trial for lead product TVGN 489 with no dose limiting toxicities or treatment-related adverse events observed. Trial showed correction of lymphopenia, reduction of inflammatory markers and viral load in patients infected with Delta and Omicron variants.

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: T cell therapiesCD8+ cytotoxic T lymphocytesGenetically unmodified precision T cell therapies
Industry: Biotech

Drug pipeline

11 assets

SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes

10 more assets in the full pipeline.

Request access →

Partnerships

Microsoft (for AI implementation)

Beyond the preview

Go deeper on Tevogen Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tevogen Bio.

Explore the full profile